Stocks making the biggest moves premarket: Salesforce, First Solar, Biogen & more

Several stocks rose after analyst upgrades: Salesforce gained 4%, First Solar 2.4%, Biogen 2%, SLM 2% and Mattel more than 1%; IREN rose 5.3% after a report of a multiyear cloud-computing deal with Anthropic. Upgrade rationales included AI-driven software dependence, solar demand and pricing power, Biogen clinical readouts expected in 2027, SLM's valuation despite a 15% year-to-date decline, and perceived value in toy stocks amid takeover speculation.

Analysis

The common signal is analyst-driven rerating, not new earnings evidence; avoid treating the morning gains as confirmation of fundamentals. CRM’s AI thesis turns on paid seat retention, upsell and inference costs—not usage anecdotes. If AI features preserve seat counts and expand revenue per customer, incumbents benefit; if customers consolidate seats or shift budgets to model providers, CRM’s value capture may lag. Verify subsequent guidance and disclosed AI monetization.

IREN is the most consequential potential catalyst, but the reported Anthropic arrangement is not yet enough to underwrite returns. Contract duration, committed capacity, pricing, power availability, capex and customer concentration determine whether this is durable cloud revenue or a capital-intensive pivot. Renewable power may help secure compute demand, while grid constraints and buildout financing can absorb value. Relative winners could include data-center power and equipment suppliers; legacy miners without contracted compute demand may face a higher bar for valuation.

FSLR’s pricing power is vulnerable to policy changes and cheaper competing modules; demand growth alone does not secure margins. BIIB’s 2027 readouts are too distant for a near-term catalyst trade absent nearer clinical or commercial evidence. SLM remains exposed to borrower performance and changes in student-loan policy. MAT takeover speculation can lift the whole toy group, but a premium is not a standalone investment thesis; deal failure would unwind some optionality.

Contrarian read: the most attractive setup may be to wait. Upgrades can create short-term momentum, but most cited catalysts are either unquantified or far-dated. A reversal in analyst assumptions, weaker guidance, or confirmation that IREN’s deal requires substantial uncontracted investment would challenge the positive tape.

Key Decisions for Investors

• IREN: Keep on a catalyst watchlist rather than chase the reported pop. Reassess only after verifying contract economics, committed compute capacity, capex, power access and customer concentration; these are the key missing inputs.
• CRM: Do not buy solely on the AI-deepens-dependence thesis. Track seat trends, AI-related revenue/upsell and margins; fading seat growth or rising costs without monetization would falsify the thesis.
• FSLR: Prefer waiting for a better entry or expressing exposure relative to a broad solar basket; monitor pricing, policy support and company guidance for evidence that demand converts into durable margins.
• BIIB and MAT: Avoid paying up for 2027 clinical optionality or takeover speculation without nearer evidence. For MAT, treat a failed or absent transaction catalyst as a downside risk; for BIIB, reassess as readouts approach.
• SLM: Keep neutral pending evidence on credit performance and policy. A deterioration in borrower metrics or adverse student-loan policy developments would outweigh a valuation-based upgrade.